Sanofi ADR (SNY) aktie

Q453 dage siden

Ordredybde

Lukket

Antal

Køb

1

Sælg

Antal

9

Seneste handel

Tid	Pris	Antal	Købere	Sælgere
-		-	-	-

Volumenvægtet gennemsnitspris

-

VWAP

-

Omsætning (USD)

44.047.730

Mæglerstatistik

Ingen data fundet

Corporate Actions

Udbyttedato	X-dag	Udbytte/aktie
23.6.2023	30.5.2023	1,9 USD

Data hentes fra Morningstar

Relaterede Produkter

Der findes ingen Nordnet Markets Certificates med det underliggende værdipapir. Vis andre Certificates

Andre har kigget på

Nyheder og Analyser

Nyheder og/eller generelle investeringsanbefalinger eller et uddrag af disse på denne side og i relaterede links er produceret og leveret af den angivne leverandør. Nordnet har ikke deltaget i udarbejdelsen af materialet, og vi har ikke gennemgået eller foretaget ændringer i materialet. Læs mere om investeringsanbefalinger.

Q453 dage siden

Corporate Actions

Udbyttedato	X-dag	Udbytte/aktie
23.6.2023	30.5.2023	1,9 USD

Data hentes fra Morningstar

Nyheder og Analyser

Nyheder og/eller generelle investeringsanbefalinger eller et uddrag af disse på denne side og i relaterede links er produceret og leveret af den angivne leverandør. Nordnet har ikke deltaget i udarbejdelsen af materialet, og vi har ikke gennemgået eller foretaget ændringer i materialet. Læs mere om investeringsanbefalinger.

Relaterede Produkter

Der findes ingen Nordnet Markets Certificates med det underliggende værdipapir. Vis andre Certificates

Shareville

Burgundia
7. dec. 2022
Burgundia
7. dec. 2022
Står til at få en Opiodsag afvist

_esc
17. apr. 2020 · Slået op via Shareville
_esc
17. apr. 2020 · Slået op via Shareville
07:00 Sanofi to present Phase 2 detailed results of its brain-penetrant BTK inhibitor in relapsing multiple sclerosis

_esc
16. apr. 2020 · Slået op via Shareville
_esc
16. apr. 2020 · Slået op via Shareville
SANOFI AND LUMINOSTICS TO JOIN FORCES ON DEVELOPING BREAKTHROUGH COVID-19 SMARTPHONE-BASED SELF-TESTING SOLUTION
_esc
16. apr. 2020 · Slået op via Shareville
_esc
16. apr. 2020 · Slået op via Shareville
Ja, kom nyheter i går også.. bare et lite 'flax-lodd' just in case. Er stort sett i cash nå uansett.

_esc
14. apr. 2020 · Slået op via Shareville
_esc
14. apr. 2020 · Slået op via Shareville
SANOFI AND GSK TO JOIN FORCES IN UNPRECEDENTED VACCINE COLLABORATION TO FIGHT COVID-19 Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19

Deltag i samtalen på Shareville

Tilslut dig et fællesskab med passionerede investorer.

Læs mere

Kommentarerne ovenfor kommer fra Nordnets sociale netværk Shareville, og er ikke blevet redigeret eller gennemgået af Nordnet. Det betyder ikke, at Nordnet giver investeringsrådgivning eller investeringsanbefalinger. Nordnet påtager sig ikke noget ansvar for kommentarerne.

Q453 dage siden

Corporate Actions

Udbyttedato	X-dag	Udbytte/aktie
23.6.2023	30.5.2023	1,9 USD

Data hentes fra Morningstar

Shareville

Burgundia
7. dec. 2022
Burgundia
7. dec. 2022
Står til at få en Opiodsag afvist

_esc
17. apr. 2020 · Slået op via Shareville
_esc
17. apr. 2020 · Slået op via Shareville
07:00 Sanofi to present Phase 2 detailed results of its brain-penetrant BTK inhibitor in relapsing multiple sclerosis

_esc
16. apr. 2020 · Slået op via Shareville
_esc
16. apr. 2020 · Slået op via Shareville
SANOFI AND LUMINOSTICS TO JOIN FORCES ON DEVELOPING BREAKTHROUGH COVID-19 SMARTPHONE-BASED SELF-TESTING SOLUTION
_esc
16. apr. 2020 · Slået op via Shareville
_esc
16. apr. 2020 · Slået op via Shareville
Ja, kom nyheter i går også.. bare et lite 'flax-lodd' just in case. Er stort sett i cash nå uansett.

_esc
14. apr. 2020 · Slået op via Shareville
_esc
14. apr. 2020 · Slået op via Shareville
SANOFI AND GSK TO JOIN FORCES IN UNPRECEDENTED VACCINE COLLABORATION TO FIGHT COVID-19 Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19

Deltag i samtalen på Shareville

Tilslut dig et fællesskab med passionerede investorer.

Læs mere

Kommentarerne ovenfor kommer fra Nordnets sociale netværk Shareville, og er ikke blevet redigeret eller gennemgået af Nordnet. Det betyder ikke, at Nordnet giver investeringsrådgivning eller investeringsanbefalinger. Nordnet påtager sig ikke noget ansvar for kommentarerne.

Ordredybde

Lukket

Antal

Køb

1

Sælg

Antal

9

Seneste handel

Tid	Pris	Antal	Købere	Sælgere
-		-	-	-

Volumenvægtet gennemsnitspris

-

VWAP

-

Omsætning (USD)

44.047.730

Mæglerstatistik

Ingen data fundet

Andre har kigget på

Nyheder og Analyser

Nyheder og/eller generelle investeringsanbefalinger eller et uddrag af disse på denne side og i relaterede links er produceret og leveret af den angivne leverandør. Nordnet har ikke deltaget i udarbejdelsen af materialet, og vi har ikke gennemgået eller foretaget ændringer i materialet. Læs mere om investeringsanbefalinger.

Relaterede Produkter

Der findes ingen Nordnet Markets Certificates med det underliggende værdipapir. Vis andre Certificates

United States of AmericaUnited States of AmericaSanofi ADR(SNY)

Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial

Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis

Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance

Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)

Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review

ALTUVIIIO™ approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS)

Press release: New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease

Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection

Press Release: Sanofi announces change in R&D leadership

Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial

Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis

Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance

Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)

Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review

ALTUVIIIO™ approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS)

Press release: New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease

Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection

Press Release: Sanofi announces change in R&D leadership

Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial

Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis

Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance

Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)

Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review

ALTUVIIIO™ approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS)

Press release: New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease

Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection

Press Release: Sanofi announces change in R&D leadership

Om værdipapiret

Sanofi ADR
(SNY)